Sanofi and Regeneron Pharmaceuticals faced notable share price declines after mixed results from late-stage clinical trials of their experimental drug, itepekimab, targeting chronic obstructive pulmonary disease (COPD) in former smokers. On Friday, Sanofi disclosed that its phase III trials produced diverging efficacy data. In one study, the drug demonstrated a 27% reduction in the rate of COPD exacerbations, suggesting meaningful therapeutic potential. However, parallel research failed to replicate these benefits, despite earlier, more positive interim outcomes.

Ola Electric Mobility Ltd. $OLAELEC.NS recorded its sharpest intraday selloff since April 7, as quarterly results highlighted deepening losses and a sharp revenue contraction. The company reported a net loss of 8.7 billion INR (approximately 102 million USD) for the quarter ending March 31. This figure represents more than a twofold increase compared to last year's 4.16 billion INR loss. Concurrently, revenue dropped 62% year-on-year to 6.11 billion INR, indicating persistent headwinds in market demand and operational efficiency.

Shares of NetEase Inc. $9999.HK, a major force in interactive entertainment, are trading just 7% below their 2021 historical peak—suggesting the company is on the cusp of setting a new price benchmark after more than four years. NetEase, the studio behind viral sensations like Eggy Party, has emerged as a top gainer among Chinese technology firms and leading global gaming equities, a distinction amplified in recent months.